Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2009
Business Overview: The Company develops, manufactures, and sells biotechnology products (cytokines, antibodies, assay kits) and hematology calibrators/controls. Operations are conducted through three reportable segments: Biotechnology (R&D Systems, BiosPacific, R&D China), R&D Europe, and Hematology. The Company is a leading global supplier of cytokines and cytokine-related reagents.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 | Fiscal 2007 |
|---|---|---|---|
| Net Sales | $263.96 million | $257.42 million | $223.48 million |
| Gross Margin | 79.0% | 79.5% | 79.1% |
| Operating Income | $150.78 million | $144.29 million | $124.15 million |
| Net Earnings | $105.24 million | $103.56 million | $85.11 million |
| Diluted EPS | $2.78 | $2.64 | $2.15 |
| Cash from Operations | $111.32 million | $115.32 million | $90.50 million |
| Cash & Investments | $202.89 million | $206.35 million | $164.77 million |
| Long-Term Debt | $0 | $0 | $0 |
| Working Capital | $239.94 million | $238.19 million | $195.65 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 2.5% to $263.96 million. Excluding the unfavorable impact of foreign currency exchange rates (primarily a stronger U.S. dollar), sales increased 5.9%.
- Profitability: Net earnings increased 1.6% to $105.24 million. Gross margins declined slightly to 79.0% from 79.5%, primarily due to lower margins at R&D Europe caused by unfavorable exchange rates.
- Segment Performance:
- Biotechnology: Sales increased 5.0% driven by volume growth across international distributors and academic customers.
- R&D Europe: Reported sales decreased 4.2% due to currency headwinds; however, volume increased 7.2% at constant currency rates.
- Hematology: Sales increased 9.2% due to increased volume.
- Expenses: Selling, general, and administrative (SG&A) expenses decreased 9.7% to $33.16 million, largely due to reduced profit sharing/bonus expenses and favorable currency translation. R&D expenses increased 5.2% to $23.56 million to support the introduction of over 1,400 new products.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Capital Allocation: The Company initiated cash dividends in fiscal 2009 ($0.75 per share total) and authorized an additional $60 million for stock repurchases (totaling $210 million authorized, with $67.5 million remaining available).
- Investments: The Company holds significant equity investments in ChemoCentryx ($14.3 million), Nephromics ($4.5 million), Hemerus ($2.2 million), and ACTGen ($1.2 million). A $1.3 million distribution was received from Nephromics in fiscal 2009.
- Future Tax Rate: Expected to range from 32% to 33% for fiscal 2010.
Risks and Contingencies:
- Currency Risk: Approximately 29% of sales are in foreign currencies. A stronger U.S. dollar negatively impacted 2009 results.
- Research Spending: Revenues are dependent on spending by pharmaceutical, biotechnology, and academic/government research institutions.
- Intellectual Property: Ongoing patent interference and infringement litigation with Streck Laboratories regarding hematology controls. Management does not believe this will have a material financial impact.
- Investment Risk: Potential impairment of investments in development-stage companies if they fail to secure funding or regulatory clearance.
Investor Verification Checklist
- Currency Impact: Verify the extent to which the 2.5% revenue growth masks underlying volume growth (reported as 5.9% at constant currency) and the specific impact of the U.S. dollar strength on European margins.
- Inventory Valuation: Review the $17.7 million reserve for excess protein and antibody inventory, which is based on a two-year usage forecast requiring significant management judgment.
- Investment Portfolio: Assess the valuation and impairment risk of the $22.1 million in unconsolidated equity investments (ChemoCentryx, Nephromics, Hemerus, ACTGen), particularly given their development-stage status.
- Legal Proceedings: Monitor the status of the patent interference with Streck Laboratories regarding reticulocyte hematology controls.
- Dividend Sustainability: Confirm the Board's commitment to the new dividend policy ($0.25 per quarter) and its impact on future cash flow allocation versus R&D and capital expenditures.